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Abstract: The early detection of HER2 (human epidermal growth factor receptor 2) status 
in breast cancer patients is very important for the effective implementation of anti-HER2 
antibody therapy. Recently, HER2 detections using antibody conjugated quantum dots 
(QDs) have attracted much attention. QDs are a new class of fluorescent materials that 
have superior properties such as high brightness, high resistance to photo-bleaching, and 
multi-colored emission by a single-light source excitation. In this study, we synthesized 
three types of anti-HER2 antibody conjugated QDs (HER2Ab-QDs) using different 
coupling agents (EDC/sulfo-NHS, iminothiolane/sulfo-SMCC, and sulfo-SMCC). As 
water-soluble QDs for the conjugation of antibody, we used glutathione coated 
CdSe/CdZnS QDs (GSH-QDs) with fluorescence quantum yields of 0.23~0.39 in aqueous 
solution. Dispersibility, hydrodynamic size, and apparent molecular weights of the GSH-
QDs and HER2Ab-QDs were characterized by using dynamic light scattering, fluorescence 
correlation spectroscopy, atomic force microscope, and size-exclusion HPLC. 
Fluorescence imaging of HER2 overexpressing cells (KPL-4 human breast cancer cell line) 
was performed by using HER2Ab-QDs as fluorescent probes. We found that the HER2Ab-
QD prepared by using SMCC coupling with partially reduced antibody is a most effective 
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probe for the detection of HER2 expression in KPL-4 cells. We have also studied the size 
dependency of HER2Ab-QDs (with green, orange, and red emission) on the fluorescence 
image of KPL-4 cells. 
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1. Introduction 
Tumor cells show overexpression of HER2 (human epidermal growth factor receptor 2) in 
approximately 20%−30% of breast cancer patients [1,2]. Thus, molecular-targeted therapy for HER2 
has a tremendous impact on breast cancer treatment. Anti-HER2 antibodies inhibit the growth of 
HER2-overexpressing breast cancer cells, and the anti-HER2 antibody therapy is most effective in 
HER2-positive breast cancer patients [3-5]. The early detection of HER2 status in breast cancer 
patients is crucial for the effective implementation of anti-HER2 antibody therapy. Currently, 
immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) are the most widely used 
methods for determining HER2 status in breast cancer patients [6]. IHC is a semi quantitative 
technique and its accuracy depends on the proficiency of the pathologist [7,8]. Although FISH analysis 
is more sensitive and quantitative than IHC in determining HER2 status, this method is complicated, 
expensive and time-consuming [9,10]. 
In a few years, HER2 detection using quantum dot (QD) based fluorescent probes have attracted 
much attention [11-22]. Compared to traditional fluorescent organic dyes and proteins, QDs have 
superior properties such as high brightness, high resistance to photo-bleaching, and multi-colored 
emission by a single source excitation. Several groups have reported staining of HER2 overexpressing 
breast cancer cells using anti-HER2 antibody conjugated QDs (HER2Ab-QDs) [11-18,20-22]. Liu et al. 
first showed the utility of QDs for immunofluorescent staining of HER2 in breast cancer SK-BR-3 
cells, and they demonstrated that the QD-based fluorescent probes offer substantial advantages over 
organic dyes in multiplex target detection [11]. Recently, Li et al. have developed QD-based 
immunofluorescence technology for the quantitative determination of HER2 expression in breast 
cancer tissues [19].  
Several kinds of conjugation methods can be used for the development of HER2Ab-Qds [23]. The 
most popular conjugation method involves the use of a zero-length crosslinker, EDC (1-ethyl-3-(3-
dimethyl-aminopropyl)carbodiimide hydrochloride for the formation of amide bonds between carboxyl 
groups (introduced to the surface of QD) and primary amines of antibody [23]. In EDC coupling 
method, there is a possibility that the antigen binding sites of the antibodies are blocked by the non-
selective formation of amide bonds at the vicinity of Fab region of antibody [16,23]. To avoid this, 
SMCC (succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate) coupling reaction can be 
used as a substitute for the selective conjugation of partially reduced antibodies to QDs. In this case, 
sulfhydyl groups (at Fc region) of reduced antibodies bind to the maleimide groups of the SMCC 
coupled QDs [23]. Besides these two methods, noncovalent conjugation of streptavidin coated QDs 
and biotinylated antibodies can be used for preparing HER2Ab-QDs [16,22]. However, the Sensors 2009, 9                 
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relationship between antibody conjugation methods and effectiveness of the resulting HER2Ab-QDs 
for cellular imaging is not clear.  
The objective of this work was to synthesis anti-HER2 antibody conjugated QDs (HER2Ab-QDs) 
prepared by different coupling methods [23] and to examine their staining abilities for HER2 
overexpressing breast cancer cells. We synthesized three types of HER2Ab-QDs using the EDC/sulfo-
NHS (3-sulfo-N-hydroxysuccinimide sodium salt), iminothiolane/sulfo-SMCC, and sulfo-SMCC 
coupling methods. As water-soluble QDs for the conjugation of anti-HER2 antibody, we used 
glutathione coated CdSe/CdZnS QDs (GSH-QDs) [24] with fluorescence quantum yields of 0.23~0.39 
in aqueous solution. In the first type of HER2Ab-QDs, primary amines of anti-HER2 antibody are 
non-selectively conjugated to the carboxy groups of GSH-QDs via EDC/sulfo-NHS coupling. In the 
second type of QDs, iminothiolane modified anti-HER2 antibodies non-selectively conjugated to the 
surface of GSH-QDs with maleimide groups of SMCC coupled GSH-QDs. In the third type, SMCC 
coupled GSH-QDs selectively conjugated to the sulfhydryl groups of reduced antibodies. The size, 
surface structure, and apparent molecular weights of GSH-QDs and HER2Ab-QDs were characterized 
by using dynamic light scattering (DLS), fluorescence correlation spectroscopy (FCS), atomic force 
microscopy (AFM), and size-exclusion HPLC. Staining ability of the HER2Ab-QDs for HER2 
overexpressing breast cancer cells (KPL4-cells) was examined by laser confocal fluorescence imaging. 
We found that the HER2Ab-QDs prepared by SMCC coupling with reduced antibodies were most 
effective in concern to the stability of the antibody conjugated complex and the detection of HER2 
expression in breast cancer cells. We have also examined the size dependency of HER2Ab-QDs (with 
green, orange, and red emission) on the cellular uptake and localization. 
2. Results and Discussion 
2.1. Surface Modification of QDs with Glutathione (GSH) 
 
The synthesis of highly fluorescent QDs is generally performed in organic solvents such as 
trioctylphosphine oxide (TOPO) and hexadecylamine (HDA) at high temperature (>200 °C) [25-29]. 
The resulting QDs are coated with hydrophobic organic compounds so that they are not soluble in 
water. For bioconjugation, QD surface should be modified with functional groups such as carboxyl 
groups and amines. In this study, we used glutathione (GSH, reduced form) as a coating agent for the 
surface modification of TOPO/HDA capped QDs [30-32]. GSH is a natural thiol compound   
(γ-L-glutanyl-L-cystenylglycine) that exists in most organs at mM levels [33,34], and the compound is 
not harmful like synthetic thiol compounds (e.g. mercaptoacetic acid and mercapotethanol). In addition, 
it has been shown that the GSH has a property to detoxify Cd
2+ ions in cellular level due to its 
chelating capability [35]. 
Figure 1 shows the surface coating procedure for preparing GSH coated QDs (GSH-QDs). First, 
TOPO/HDA coated QDs (TOPO/HDA-QDs) are dispersed to tetrahydrofuran (THF). Then the 
aqueous solution of GSH is added to the THF solution of QDs for ligand-exchange with GSH. As a 
result of ligand exchange, GSH-coated QDs precipitate in THF-water solution. After deprotonation of 
the carboxyl groups at the QD surface, GSH-coated QDs are easily dissolved in water. Since the GSH-
coated QDs have both carboxyl groups and primary amines at their surface, various coupling agents Sensors 2009, 9                 
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can be used for antibody conjugation. In this study, we synthesized three types of antibody-conjugated 
GSH-QDs by using EDC/sulfo-NHS, iminothiolane/SMCC, and SMCC coupling agents.  
 
Figure 1. Schematic representation for the surface coating procedure with GSH. GSH 
coating is performed in a mixture of THF-water at 60 °C. Potassium t-butoxide (KOBut) is 
used for deprotonation of the carboxyl groups of GSH. 
 
 
 
 
 
2.2. Characterization of GSH-QDs 
 
2.2.1. Fluorescence quantum yields 
 
In cellular imaging, the brightness of fluorescent probes is crucial for obtaining clear images with a 
high signal to noise ratio, because cells contain intrinsic fluorophores such as aromatic amino acids, 
neurotransmitters and porphyrins that emit in the visible region. Figure 2 shows the fluorescence 
spectra of GSH-QDs with the values of fluorescence quantum yields in 10 mM PBS. The fluorescence 
emission efficiencies of TOPO/HDA capped CdSe/CdZnSe QDs were very high and their quantum 
yields were 0.60, 0.45 and 0.72 in chloroform for green-, orange-, and red- emitting QDs, respectively. 
After the ligand-exchange with GSH, the quantum yields decreased to be 0.33, 0.23 and 0.39 for 
green-, orange-, and red- emitting GSH-QDs, respectively. GSH-coating retained ca. 50% of 
fluorescence efficiency after the surface modification. When the surface of the QDs was modified with 
MAA and MPA, the quantum yields of the QDs were less than 0.1. The surface modification of 
TOPO/HDA capped QDs with GSH is very simple and useful for preparing highly fluorescent water-
soluble QDs. 
 
2.2.2. Hydrodynamic size and dispersibility of QDs 
 
Hydrodynamic size and dispersibility of QDs are very important properties for their applications to 
cellular imaging. The particle size of QDs affects endocytosis or limits access to receptors of interest 
on cellular membranes [24,36,37]. In living tissues, QD particle size affects biodistribution and 
pharmacokinetics [38,39]. Hydrodynamic size of GSH-QDs was evaluated by using dynamic light Sensors 2009, 9                 
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scattering (DLS) and fluorescence correlation spectroscopy (FCS). Figure 3 shows DLS histogram for 
green- and orange-emitting QDs in PBS buffer. The histogram shows that the GSH-QDs are 
monodisperse particles, and their hydrodynamic diameters are 4.5 ± 0.6 nm and 5.9 ± 0.5 nm for 
green- and orange-emitting QDs, respectively. For the red-emitting GSH-QDs with a 650 nm emission 
peak, reliable DLS data was not obtained due to the overlapping between QD fluorescence around 650 
nm and the light scattering from a 633 nm He/Ne laser. Hence, the hydrodynamic size of the red-
emitting GSH-QDs (650 nm) was determined by using FCS  [40-44]. 
Figure 2. Fluorescence spectra and quantum yields of GSH-QDs that have emission peaks 
at 540 nm (green), 585 nm (orange), and 650 nm (red) in 10 mM PBS buffer. Inset shows a 
fluorescence image of three types of GSH-QDs in PBS buffer under irradiation of a UV 
light (365 nm). 
 
 
 
 
 
 
 
 
 
 
Figure 3. Dynamic light scattering histogram for GSH-QDs in PBS buffer: (a) GSH-QDs 
(540 nm) and (b) GSH-QDs (585 nm). 
 
 
 
 
 
 
 
 
 
 
Figure 4 shows the fluorescence autocorrelation curves G(τ) for GSH-QDs (650 nm) and 
fluorescent latex beads (20 nm in diameter) in 10 mM PBS. Both the G(τ) curves can be fitted 
according to a single-component diffusion model [equation (2) in the Experimental section], indicating 
that GSH-QDs and fluorescent latex  beads  are monodisperse  in the  PBS  buffer. From the fitted 
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curves based on a single-component diffusion model, the diffusion times (τ) are determined to be 0.33 
ms and 0.96 ms for GSH-QDs (650 nm) and fluorescent latex beads (20 nm in diameter), respectively. 
Using the values of τ, the hydrodynamic diameter of the GSH-QDs (650 nm) is calculated to be 6.9 ± 
0.5 nm. The hydrodynamic size of commercially available QDs (Invitrogen, Qdot 655 ITK) with a 655 
nm peak emission is reported as ca. 19 nm in diameter [45]. GSH-QDs (650 nm) prepared by our 
method is at least two times smaller compared to the commercial QDs. 
Figure 4. Fluorescence autocorrelation curves G(τ) for red-emitting GSH-QDs (650 nm) 
and standard fluorescent beads (20 nm in diameter) in  10 mM PBS. The autocorrelation 
curves are fitted by using a single-component diffusion model (broken lines). 
 
 
 
 
 
 
 
 
 
 
 
2.2.3. Apparent molecular weights of GSH-QDs 
 
Furthermore, we evaluated the apparent molecular weights of GSH-QDs using size-exclusion 
HPLC. Figure 5 shows a size-exclusion HPLC chromatograph for standard proteins (thyroglobulin: 
670 kDa, ferritin: 450 kDa, transferrin: 80 kDa and bovine serum albumin: 66 kDa) and GSH-QDs. 
The relationship between molecular weights of the standard proteins and their retention times is almost 
linear as shown in the inset of Figure 5a. From this relationship, apparent molecular weights of GSH-
QDs can be determined. The result is summarized in Table 1 together with the values of quantum yield 
and hydrodynamic size. The apparent molecular weight of GSH-QDs increases with increasing their 
hydrodynamic diameter: 75 kDa, 150 kDa, and 300 kDa for GSH-QD (540 nm), GSH-QD (585 nm), 
and GSH-QD (650 nm), respectively The molecular weight of GSH-QD (585 nm) is ca. three times 
larger than that of a green fluorescent protein, GFP (27 kDa), while the size of QD is comparable to 
that of GFP having a cylindrical shape with 4.2 nm long and 2.4 nm in diameter [46]. The molecular 
weight of GSH-QD (585 nm) is comparable to that of antibody immunoglobulin G, IgG (160 kDa). In 
the case of GSH-QD (650nm), its molecular weight is two-times larger than that of IgG, while the size 
of QD is comparable to that of IgG (14.5 × 8 × 4 nm
3) [47,48].  Sensors 2009, 9                 
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Figure 5. Size-exclusion HPLC chromatograph for standard proteins (a) and GSH-QDs 
using a TSKgel G4000SW column with 10 mM PBS buffer as an eluent; 1) thyroglobulin 
(670 kDa), 2) ferritin (450 kDa), 3) bovine serum albumin (66 kDa), 4) transferrin (80 
kDa), 5) GSH-QD (650 nm), 6) GSH-QD (585 nm), and 7) GSH-QD (540 nm).  
Table 1. Fluorescence quantum yields, hydrodynamic diameters, and apparent 
molecular weights of GSH-QDs in 10 mM PBS buffer. 
                 GSH-QD (540 nm)         GSH-QD (585 nm)      GSH-QD (650 nm) 
  Quantum yield             0.33 
a                        0.23 
b                    0.39 
b 
  Diameter (nm)            4.5 ± 0.6
 c                5.9 ± 0.5
 c             Not determined
  
                             4.4 ± 0.2
d                        5.1± 0.3
 d                           6.9 ± 0.5
 d 
  Apparent MW (kDa)         75                         150                     300  
a Excitation: 440 nm , 
b excitation: 488 nm, 
 c evaluated by DLS, 
d evaluated by FCS 
 
2.2.4. Stability of GSH-QDs in aqueous solution 
 
Colloidal stability of QDs around the neutral pH is necessary for biomolecule conjugation, because 
most of the conjugation reactions are performed in physiological buffers. When an aqueous solution of 
GSH-QDs (PBS buffer, pH = 7.2) was preserved in the dark at 4 °C, monodispersibility of the QDs 
was maintained at least for two months. The monodispersibility of the QDs was analyzed by using 
DLS and FCS (data not shown). In contrast, when the aqueous solution of GSH-QDs was preserved 
under room light at room temperature, the QDs aggregated within one month. This instability of the 
QDs can be explained by photooxidation of GSH, which may induce the degradation of the surface of 
GSH-QD to aggregate QDs [49]. 
 
2.3. Conjugation of Anti-HER2 Antibody to GSH-QDs 
 
There are various methods for the conjugation of antibodies to functionalized QDs with carboxyl 
groups and/or primary amines [16,23,51]. We prepared three types of anti-HER2 antibody conjugated 
GSH-QDs (HER2Ab-QDs) as shown in Figure 6. In all of the HER2Ab-QDs, antibodies are covalently Sensors 2009, 9                 
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bound to the surface of QDs. In the case of EDC/sulfo-NHS coupling, NHS groups are introduced to 
the surface of GSH-QDs and the NHS groups react non-selectively with the primary amines of 
antibody to form amide bonds. For the iminothiolane/SMCC coupling, the primary amines of antibody 
are non-selectively modified with iminothiolane to introduce sulfhydryl groups to the antibody. The 
sulfhydryl groups of antibody react with the maleimide groups at the surface of SMCC activated QDs. 
In this coupling method, antibody orientation at the surface of QDs cannot be fixed due to the non-
selective conjugation of antibodies to QDs. In the case of SMCC coupling with reduced antibodies 
(prepared by DTT or cysteamine), the antigen binding sites of antibodies face outward, because the 
sulfhydryl groups of reduced antibodies bind to the maleimide groups at the surface of SMCC   
coupled QDs. 
Figure 6. Schematic representation for the coupling reactions between GSH-QDs and anti-
HER2 antibodies: a) EDC/sulfo-NHS, b) iminothiolane/sulfo-SMCC, and c) sulfo-SMCC 
coupling. 
The binding of antibody molecules to GSH-QDs was confirmed by the measurements of the 
hydrodynamic size and shape of QDs by using FCS and AFM. Figure 7 shows fluorescence 
autocorrelation curves of red-emitting GSH-QDs and HER2Ab-QDs prepared by three different 
coupling methods. The diffusion times of all types of HER2Ab-QDs are larger than that of GSH-QDs, 
showing that the antibodies are bound to GSH-QDs. From the values of diffusion times, hydrodynamic 
diameters are determined to be 7.0 ± 0.3 nm for GSH-QDs, 9.4 ± 0.5 nm for HER2Ab-QDs (SMCC 
coupling), 12 ± 0.4 nm for HER2Ab-QDs (EDC/sulfo-NHS coupling), and 12 ± 1.2 nm for HER2Ab-
QDs (iminothiolane/SMCC coupling). These results support that the whole bodies of antibody are Sensors 2009, 9                 
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bound to GSH-QDs in case of HER2Ab-QDs (EDC/sulfo-NHS coupling) and HER2Ab-QDs 
(iminothiolane/SMCC coupling), while only half bodies of antibody are bound to GSH-QDs in the 
case of HER2Ab-QDs (SMCC coupling). 
Figure 7. Fluorescence autocorrelation curves for red-emitting GSH-QDs and HER2Ab-
QDs prepared by different coupling methods: (a) HER2Ab-QD (sulfo-SMCC), (b) 
HER2Ab-QD (EDC/sulfo-NHS), and (c) HER2Ab-QD (iminothiolane/sulfo-SMCC). Inset 
shows hydrodynamic diameters of the QDs in 10 mM PBS buffer. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AFM images also confirmed the binding of antibodies to GSH-QDs (Figure 8). The images of 
GSH-QDs show spherical shapes, while all three types of HER2Ab-QDs show non-spherical shapes or 
somehow elongated shapes. Then, we compared GSH-QD structure coupled with different type of 
antibodies by using the aspect ratio. The aspect ratio of GSH-QDs was almost 1.0 [Figure 8(a)]. The 
AFM images of HER2Ab-QDs indicate that a few molecules of antibodies are bound to the surface of 
GSH-QDs and their aspect ratios were also changed. [Figure 8b,c] The aspect ratios of HER2Ab-QDs, 
which were prepared by EDC/NHS and iminothiolane/SMCC coupling methods, were 1.3 ± 0.2 and 
almost same. Since the size of anti-HER2 antibody (IgG) is comparable to the size of GSH-QDs (650 
nm), steric hindrance between antibody molecules bound at the QD surface may limit the number of 
antibodies that bind to the surface of QD. The comparison among the shapes of all three types of 
HER2Ab-QDs indicates that the whole bodies of antibody are bound to the QD surface in HER2Ab-
QDs (EDC/NHS) and HER2Ab-QDs (iminothiolane/SMCC). In contrast, only half bodies of antibody 
are bound to the QD surface in case of HER2Ab-QDs prepared by SMCC coupling to reduced 
antibodies. As the steric hindrance of half bodies of antibody was less than that of whole bodies of 
antibody, the prepared HER2Ab-QDs had the various aspect ratio [Figure 8(d)]. The changing of 
aspect ratio indicated that the binding of antibodies to GSH-QDs. 
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Figure 8. AFM images (left panel) and the histogram of aspect ratio (right panel) of red-
emitting GSH-QDs a) and HER2Ab-QDs prepared by the coupling reaction using b) 
EDC/sulfo-NHS, c) iminothiolane/sulfo-SMCC, and d) sulfo-SMCC. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
 
 
 
2.4. Confocal Fluorescence Imagimg of KPL-4 Breast Cancer Cells  
 
We first examined staining abilities and colloidal stabilities of three types of HER2Ab-QDs for 
fluorescence imaging of KPL-4 human breast cancer cells. Figure 9 shows confocal fluorescence 
images of KPL-4 cells after 30 min incubation of HER2Ab-QDs (green, 540 nm) prepared by three Sensors 2009, 9                 
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different coupling methods. All three types of HER2Ab-QDs clearly stained the KPL-4 cells. However, 
in the case of the HER2Ab-QDs prepared by using EDC/sulfo-NHC and iminothiolane/sulfo-SMCC 
coupling, QD aggregations were observed in the images (Figure 9a,b). HER2Ab-QDs prepared by 
SMCC coupling to reduced antibodies showed no aggregation of the QDs and the cells were intensely 
stained compared to other two types of HER2Ab-QDs (Figure 9c). QD aggregations observed in 
Figure 9a,b may have resulted from the instability of HER2Ab-QDs in the culturing medium (DMEM). 
The fluorescence image of KPL-4 cells (Figure 9d-2) in the absence of QDs shows no fluorescence 
signals, indicating that the fluorescence signals in Figure 9a-c dose not result from autofluorescence of 
KPL-4 cells. Among all three types of QDs, HER2Ab-QDs conjugated by SMCC coupling method 
was most stable and effective as a fluorescent probe for imaging of KPL-4 cells. It should be noted that 
the green-emitting HER2Ab-QDs are distributed in cytosol as well as cell membrane, indicating that 
the cellular uptake of HER2Ab-QDs occurs by macropinocytosis or endocytosis because of the small 
size of green-emitting QDs compared to remaining two types of   
QDs [51]. It has been reported that the particle size of QDs affects endocytosis or limits access to 
receptors of interest on cellular membranes [24,36,37]. We further examined the size effects of 
HER2Ab-QDs (with green, orange, and red emission) on the fluorescence imaging of HER2 receptors 
in KPL-4 cells. 
Figure 9. Fluorescence images of KPL-4 cells in the presence (a-c) and absence (d) of 
green-emitting (540 nm) HER2Ab-QDs prepared by using three different coupling agents: 
a) EDC/sulfo-NHS, b) iminothiolane/sulfo-SMCC, and c) sulfo-SMCC. PBS solutions (20 
nM) of the HER2Ab-QDs were incubated with KLP-4 cells for 30 min at 37 °C. QDs were 
excited at 405 nm and confocal images were taken with a 490-540 nm filter. Green spots in 
white circles are attributed to QD aggregates. KPL-4 cells in the absence of green-emitting 
QDs show no cellular autofluorescence signals: differential interference contrast image  
(d-1) and fluorescence image (d-2).   
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Figure 10. Multicolor confocal images of KPL-4 cells after incubation of HER2Ab-QDs 
(540 nm, 585 nm and 650 nm) prepared by SMCC coupling with reduced anti-HER2 
antibodies. PBS solutions of the HER2Ab-QDs  (10 nM) were incubated with KLP-4 cells 
for 30 min at 37 °C. QDs were excited at 405 nm. Confocal images are taken with a  
490-540 nm filter for HER2Ab-QD (540 nm), a 575-620 nm filter for HER2Ab-QD   
(585 nm), and a 655-755 nm filter for HER2Ab-QD (650 nm). White scale bars represent 
20 μm length. 
 
Figure 10 shows the confocal images of KPL-4 and HeLa cells stained with green-, orange-, and 
red-emitting HER2Ab-QDs. HeLa cells are used as a negative control (expressing low levels of HER2 
membrane receptors) [52]. The fluorescence images were taken after 30 min incubation of the KPL-4 
and HeLa cells with HER2Ab-QDs solution (10 nM). Compared to HeLa cells, KPL-4 cells were well 
stained by HER2Ab-QDs due to specific binding of the QDs to HER2 receptors. Interestingly, the size 
of HER2Ab-QDs significantly affects on the internalization of the QDs in the KPL-4 cells (Figure 10 a). 
In the green-emitting HER2Ab-QDs (7 nm in diameter), the QDs are distributed at both cell membrane 
and cytosol. In contrast, orange- and red-emitting HER2Ab-QDs (ca. 12 nm each) are localized at the 
cell membranes. However, internalization of the orange- and red-emitting HER2Ab-QDs into cytosol 
was observed by further incubation of cells (>1 hour) with the QDs solution. The difference of the 
HER2Ab-QD staining between KPL-4 and HeLa cells indicates that the cellular uptake of HER2Ab-
QDs in KPL-4 cells is receptor mediated and directed by the complex of the QDs and HER2 receptors 
at cell surface. The cellular uptake of red-emitting HER2Ab-QDs after 1.5 hrs incubation of KPL-4 
cells is shown in Figure 11 with the control data using SMCC conjugated QDs (SMCC-QDS) and anti-
green fluorescent protein antibody conjugated QDs (GFP-QDS). SMCC-QDs and anti-GFP QDs are 
expected to have non-binding abilities to the surface of KPL-4 cells. As can be seen from the Figure 11, 
the cellular uptake of QDs was specific to the HER2Ab-QDs incubated cells. SMCC-QDs and anti-
GFP QDs did not stain the cell surface. This result shows that the red-emitting QDs enter to the KPL-4 Sensors 2009, 9                 
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cells by mediation of HER2 receptors at the cell surface. The size of HER2Ab-QDs may affect the 
accessibility or binding ability of the QDs to HER2 receptors present on the cell surface. The smaller 
HER2Ab-QDs may be rapidly taken up into the cells by their stronger binding ability to the receptors. 
The use of larger (red-emitting) HER2Ab-QDs is more effective for the quantitative elucidation of the 
HER2 expression at cell surface. 
Figure 11. Fluorescence images of KPL-4 cells after incubation of red-emitting QDs for 
1.5 hrs, with their differential interference contrast images: a) SMCC-QDs, b) anti-GFP 
QDs and c) HER2Ab-QDs (650 nm) prepared by SMCC coupling with reduced anti-HER2 
antibodies. 
 
3. Experimental Section  
3.1. Chemicals 
  
Cadmium 2,4-pentanedionate (98%) was purchased from Alfa Aesar. Stearic acid, potassium t-
butoxide, 2-mercaptoethanol and ZnEt2 (1M hexane solution) were purchased from Wako Chemicals 
(Japan). Tri-n-octylphosphine (TOP), tri-butylphosphine (TBP), tri-n-octylphosphine oxide (TOPO), 
hexamethyldisilathiane, and hexadecylamine (HDA) were purchased from Tokyo Kasei (Japan). 
Selenium (powder, 99.999%), 2-iminothiolane hydrochloride, and DL-dithiothreitol (DTT) were 
purchased from Sigma-Aldrich. Dimethylcadmium (10 wt% in hexane) was purchased from Strem 
Chemicals. 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC) and sulfo-
succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carbxylate (sulfo-SMCC) were purchased from 
Pierce. Sulfo-NHS (3-sulfo-N-hydroxysuccinimide sodium salt) was purchased from Molecular 
Bioscience. Anti-HER2 antibody (Herceptin) was purchased from Chugai Seiyaku (Japan). Anti-GFP 
polyclonal antibody was kindly gifted from Medical & Biological Laboratories (Japan). Thyroglobulin 
(from bovine thyroid), bovine serum albumin, and ferritin (type I from horse spleen) were purchased 
from Sigma-Aldrich. Transferrin (apo from human) was purchased from Wako Chemicals (Japan). 
Other chemicals used were of analytical reagent grades. Sensors 2009, 9                 
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3.2. QD Synthesis 
 
3.2.1. Preparation of Se (TBP) and Cd-Zn-S stock solution  
   
All procedures were performed under argon atmosphere. One hundred mg of selenium (powder) 
was added to 1 mL of TBP at room temperature. Selenium was easily dissolved to TBP by sonication 
using a bath-type sonicator (D150H, Delta). Two mL (2 mmol) of ZnEt2 (1M hexane solution) and 
0.57 mL (0.5 mmol) of CdMe2 were added to 7.0 mL of TOP. Then, 0.52 mL (2.5 mmol) of 
hexamethyldisilathiane was added to the CdMe2-ZnEt2/TOP solution. The stock solutions were stored 
in argon atmosphere. 
 
3.2.2. Synthesis of CdSe/CdZnS with a 540 nm emission peak 
  
A mixture of 1 g of TOPO, 3 g of HDA, 66 mg of cadmium 2,4-pentanedionate, and 250 mg of 
stearic acid was loaded into a 25 mL three-necked flask and heated at 200 °C under an argon 
atmosphere. After stirring for 10 min at 200 °C, 1 mL of the stock solution of Se (100 mg/mL TBP) 
was swiftly added, and the temperature of the solution was lowered to 150 °C. At this temperature, the 
growth of CdSe QDs was monitored by measurements of their fluorescence spectra. When the 
emission maximum reached to 515 nm, the three-necked flask was removed from the heater and the 
temperature of solution was lowered to 50
 °C. Then ca. 10 mL of ethanol was added to precipitate 
CdSe QDs. The precipitation of QDs was separated by centrifuge and was redissolved in 10 mL of 
chloroform. The QD solution was loaded into a 25 mL three-necked flask, and the chloroform was 
evaporated under reduced pressure. After evaporation of chloroform, 1 g of TOPO and 3 g of HDA 
were added to the flask and the mixture was heated to 160 °C under an argon atmosphere. After 
stirring for 10 min at 160 °C, 0.25 ml of a Cd-Zn-Se stock solution was added dropwise under 
vigorous stirring. Then the temperature of solution was decreased to 100 °C and the solution was 
stirred for 5 hrs at this temperature. After the temperature was lowered to 50 °C, CdSe/CdZnS QDs 
were precipitated by addition of excess methanol and separated by centrifuge. The precipitated QDs 
were redissolved to 20 mL of tetrahydrofuran. 
 
3.2.3. Synthesis of CdSe/CdZnS with a 585 nm emission peak   
 
The mixture of 1 g of TOPO, 3 g of HDA, 66 mg of cadmium 2,4-pentanedionate, and 250 mg of 
stearic acid was loaded into a 25 mL three-necked flask and heated at 250 °C under an argon 
atmosphere. After stirring for 10 min at 250 °C, 0.6 mL of the stock solution of Se (100 mg/mL TBP) 
was swiftly added, and the temperature of the solution was lowered to 200 °C. At this temperature, the 
growth of CdSe QDs was monitored by measurements of their fluorescence spectra. When the 
emission maximum reached to 570 nm, the three-necked flask was removed from the heater and the 
temperature of solution was lowered to 50
 °C. Then ca. 10 mL of ethanol was added to precipitate 
CdSe QDs. The precipitation of QDs was separated by centrifuge and was resolved in 10 mL of 
chloroform. The QD solution was loaded into a 25 mL three-necked flask, and the chloroform was 
evaporated under reduced pressure. After evaporation of the chloroform, 1 g of TOPO and 3 g of HDA Sensors 2009, 9                 
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were added to the flask and the mixture was heated to 180 °C under an argon atmosphere. After 
stirring for 10 min at 180 °C, 0.25 mL of a Cd-Zn-Se stock solution was added dropwise under 
vigorous stirring. Then the temperature of solution was decreased to 100 °C and the solution was 
stirred for 5 hrs at this temperature. After the temperature was lowered to 50 °C, CdSe/CdZnS QDs 
were precipitated by addition of excess methanol and separated by centrifugation. The precipitated 
QDs were redissolved to 20 mL of tetrahydrofuran. 
 
3.2.4. Synthesis of CdSe/CdZnS with a 650 nm emission peak    
  
 The mixture of 1 g of TOPO, 3 g of HDA, 66 mg of cadmium 2,4-pentanedionate and 250 mg of 
stearic acid was loaded into a 25 mL three-necked flask and heated at 320 °C under an argon 
atmosphere. After stirring for 30 min at 320 °C, 0.2 mL of the stock solution of Se (100 mg/mL TBP) 
was swiftly added, and the temperature of the solution was lowered to 300 °C. At this temperature, the 
growth of the CdSe QDs was monitored by measurements of their fluorescence emission spectra. 
When the emission maximum reached to 635 nm, the temperature was lowered to 250
 °C. Then   
0.25 ml of a Cd-Zn-Se stock solution was added dropwise under vigorous stirring. By addition of the 
Cd-Zn-Se stock solution, a red shift of ca.15 nm was observed in the emission spectra. Then the 
temperature of the solution was lowered to 100 °C and the solution was stirred for 5 hours at this 
temperature. After the temperature was lowered to 50 °C, QDs were precipitated by addition of excess 
methanol and separated by centrifugation. The precipitated QDs were redissolved in 20 mL of 
tetrahydrofuran. 
 
3.3. Surface Modification of CdSe/CdZnS QDs with Glutathione (GSH) 
  
To 1 mL of the tetrahydrofuran solution of CdSe/CdZnS QDs prepared according to the above 
method, 1 mL of GSH (200 mg/mL) was slowly added, and the mixture was heated to 60 °C. The 
resulting precipitates of GSH-coated QDs were separated by centrifugation and washed with water to 
remove tetrahydrofuran. To the QD precipitates, 1 mL of an aqueous solution (100 mg/mL) of 
potassium t-butoxide was added, and the solution was sonicated for 5 min using a bath-type sonicator. 
The aqueous solution of QDs was passed through a 0.2 μm membrane filter, and excess GSH and 
potassium t-butoxide were removed by dialysis (Spectrum dialysis membrane, MWCO: 50,000) using 
10 mM PBS buffer. The concentration of GSH-coated QDs was estimated by using fluorescence 
correlation spectroscopy (FCS). The particle number of the QDs in confocal volume was measured and 
the concentration was estimated using an aqueous solution of rhodamine 6G (20 nM) as a reference. 
 
3.4. Synthesis of Sulfo-SMCC Conjugated QDs (SMCC-QDs)  
  
One hundred μL of sulfo-SMCC (1 mM) in water was added to 1 mL of GSH-QDs (1 μM) in PBS 
buffer, and the solution was incubated for 30 min. Unreacted maleimide groups of sulfo-SMCC were 
quenched by 5 μL of mercaptoethanol (1 mM aqueous solution). To remove unbound SMCC and 
mercaotoethanol, the solution was passed through a Nap
TM-5 column with PBS buffer as an eluent. 
The QD solution was centrifuged at 15,000 G for 5 min to remove aggregated QDs. Sensors 2009, 9                 
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3.5. Conjugation of Anti-HER2 Antibody to QDs (HER2Ab-QDs)  
 
3.5.1. EDC/sulfo-NHS coupling 
 
One hundred μL of aqueous solution (1mM) of EDC was added to 1 μL of GSH-QDs (1 μM) in  
10 mM PBS buffer. Then, 250 μL of sulfo-NHS (1mM) was added to the QD solution. After 1 hour, 
the solution was passed through a Nap
TM-5 column (Sephadex G-25, GE Healthcare) with water as an 
eluent to remove unreacted EDC and sulfo-NHS. To the eluted solution, 1 mL of an aqueous solution 
of anti-HER2 antibody (1 mg/mL) was added under gentle stirring, and the solution was incubated for 
1 hour for antibody conjugation at RT. Unreacted NHS groups were quenched by addition of 10 μL of 
mercaptoethanol (10 mM aqueous solution). Unconjugated antibodies and excess mercaptoethanol 
were removed by dialysis (300 kDa cellulose acetate membrane, Harvard Apparatus) using 10 mM 
PBS buffer. The dialyzed QD solution was passed through a 0.2 μm membrane filter to remove 
aggregated QDs. 
 
3.5.2. Iminothiolane/sulfo-SMCC coupling 
 
Antibody was modified with iminothiolane for use of SMCC coupling reaction. Twenty μL of   
2-iminothiolane hydrochloride (3.6 mM) was added to 1 mL of anti-HER2 antibody solution (1 mg/mL 
in PBS), and the mixture was incubated for 1 hr at RT. To remove unconjugated iminothiolane, the 
solution was passed through a Nap
TM-5 column with water as an eluent: this iminothiolane modified 
antibody solution was used for the conjugation of SMCC coupled QDs. Next, GSH-QDs was modified 
with sulfo-SMCC. 100 μL of sulfo-SMCC (1 mM) in water was added to 1 mL of GSH-QDs (1 μM) in 
PBS buffer, and the solution was incubated for 30 min. To remove unreacted SMCC, the solution was 
passed through a Nap
TM-5 column with water as an eluent. To this solution, the iminothiolane modified 
antibody solution was added under gentle stirring, and the mixture was incubated for 1 hr at room 
temperature. Unreacted maleimide groups of sulfo-SMCC were quenched by 10 μL of 
mercaptoethanol (10 mM aqueous solution). Unconjugated antibody and mercaptoethanol were 
removed by dialysis (300 kDa cellulose acetate membrane, Harvard Apparatus) using 10 mM PBS 
buffer. The dialyzed QD solution was passed through a 0.2 μm membrane filter to remove   
aggregated QDs. 
 
3.5.3. Sulfo-SMCC coupling   
 
One mg of anti-HER2 antibody was dissolved to 1 mL of water and then 20 μL of DTT (1M) was 
added to the antibody solution. After 1 hr, the solution was dialyzed (Spectrum dialysis membrane, 
MWCO: 50,000) by using 10 mM PBS buffer. Next, GSH-QDs were modified with sulfo-SMCC.  
100 μL of aqueous solution of sulfo-SMCC (1mM) aqueous solution was added to 1 mL of GSH-QDs 
(1 μM, PBS buffer), and the mixture was incubated for 30 min at RT. To remove unreacted SMCC, the 
solution was passed through a Nap
TM-5 column with water as an eluent. To this solution, 1 mL of the 
reduced antibody (ca. 1 mg/mL) was added under gentle stirring, and the solution was incubated for  
1 hour for antibody conjugation. Unreacted maleimide groups of sulfo-SMCC were quenched by   Sensors 2009, 9                 
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10  μL of mercaptoethanol (10 mM aqueous solution). Unconjugated antibodies and excess 
mercaptoethanol were removed by dialysis (300 kDa cellulose acetate membrane, Harvard Apparatus) 
using 10 mM PBS buffer. The dialyzed QD solution was passed through a 0.2 μm membrane filter to 
remove aggregated QDs. 
 
3.6. Synthesis of Anti-GFP Polyclonal Antibody Conjugated QDs (anti-GFP QDs)  
 
Fifty μg of anti-GFP polyclonal antibody was dissolved to 100 μL of water and then 1 μL of DTT 
(1M) was added to the antibody solution. After 1 hr, the solution was dialyzed (Spectrum dialysis 
membrane, MWCO: 50,000) using 10 mM PBS buffer. Next, GSH-QDs were modified with sulfo-
SMCC. Five μL of aqueous solution of sulfo-SMCC (1 mM) aqueous solution was added to 50 μL of 
GSH-QDs (1 μM, PBS buffer), and the mixture was incubated for 30 min at RT. To remove unreacted 
SMCC, the solution was passed through a Nap
TM-5 column with water as an eluent. To this solution, 
100 μL of the reduced antibody (ca. 0.5 mg/mL) was added under gentle stirring, and the solution was 
incubated for 1 hr for antibody conjugation. Unreacted maleimide groups of sulfo-SMCC were 
quenched by 5 μL of mercaptoethanol (1 mM aqueous solution). Unconjugated antibodies and excess 
mercaptoethanol were removed by dialysis (300 kDa cellulose acetate membrane, Harvard Apparatus) 
using 10 mM PBS buffer. The dialyzed QD solution was passed through a 0.2 μm membrane filter to 
remove aggregated QDs. 
 
3.7. Characterization of QDs 
   
Fluorescence spectra of QDs were measured with a FP-6200 spectrofluorometer (JASCO). 
Emission efficiencies of QDs were evaluated as absolute quantum yields using a quantum yield 
measurement system (C10027, Hamamatsu Photonic). The absolute quantum yield (QY) is defined as 
QY = PNem  /PNab, where PNem and PNab are the number of emitted and absorbed photons by 
fluorescence materials. Excitation wavelengths were set to 440 nm for green-emitting QDs (540 nm 
emission), and 488 nm for orange-emitting and red-emitting QDs (540 nm and 650 nm emission).  
The hydrodynamic diameters of QDs were evaluated by using dynamic light scattering (DLS) and 
fluorescence correlation spectroscopy (FCS). DLS data were collected by using a Malvern DLS 
apparatus (Nano-ZS) with a 633 nm He/Ne laser.  Fluorescence autocorrelation curves were measured 
by using a compact FCS system (C9413-01MOD, Hamamatsu Photonics) with a 473 nm 
semiconductor laser as an excitation light source.  
FCS uses the fluctuations of the fluorescence intensity in a tiny confocal volume to determine the 
diffusion times of fluorescent particles [52]. Fluctuations in the fluorescence intensities I(t) can be 
analyzed by using the autocorrelation function Gτ): 
G(τ) =
< I(t)I(τ + t) >
< I(t) >
2                                       (1) 
where the symbol < > stands for the ensemble average.  
If a three-dimensional Gaussian profile in the confocal volume of the lateral radius ωo and axial 
radius ωz was assumed, equation (1) for a one-component diffusion can be expressed as: Sensors 2009, 9                 
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where, τd = ωo
2/4D. N is the average number of fluorescent particles in the excitation volume and τd is 
the diffusion time of the fluorescent particles, depending on the diffusion constant D and ωo. Using the 
Stokes-Einstein relationship (D = kBT/6pηr), the hydrodynamic diameter dQD of QDs can be calculated 
from the following equation:  
dQD = dST ×
τQD
τST
                                                                 (3) 
where dST is the diameter of a standard particle, and τQD and τST are the diffusion times of QDs and the 
standard particles, respectively. As a standard particle, we used fluorescent latex beads (20 nm in 
diameter, Molecular Probe, Inc.). 
The images of atomic force microscopy (AFM) were acquired with SPI-3800N (Seiko Instruments 
Inc.) and Si cantilever (f=134 kHz, C=16 N/m, Seiko Instruments Inc.) in tapping mode. A drop of QD 
solution (10 nM) was spotted onto fleshly cleaved mica (Nilaco Corporation) and was blown off after 
1min. Then the QD sample was subjected to air-drying for 12 hrs. 
Size exclusion column chromatography was performed with a HPLC system (Hitachi L-2130 and 
L-2400) using TSKgel G4000SW column (7.8 mm×30 cm, TOSOH, Japan). Twenty mL of QD 
solution (:10 mM PBS) was injected to the column and eluted by 10 mM PBS at room temperature 
with a flow rate of 1 mL/min. 
 
3.8. Cell Lines 
   
KPL-4 human breast cancer cell line overexpressing HER2 and HeLa cell line were subjected to 
fluorescence imaging. The KPL-4 cell line was kindly provided by Prof. J. Kurebayashi (Kawasaki 
Medical School, Kurashiki, Japan) and Prof. N. Ohuchi (Tohoku University, Japan) [54,55]. HeLa cell 
line was used as a negative control of HER2. Both cell lines were grown in four chamber glass bottom 
plates (LabTek, USA) containing Dulbecco's modified Eagle's medium (DMEM, Sigma-Aldrich, St. 
Louis, MO, USA) with 10% fetal bovine serum, 100 mg/mL penicillin, and 10 mg/mL streptomycin. 
Culture plates of both cell lines (~75% growth) were used for labeling with HER2Ab-QDs. Old culture 
medium of all plates were replaced with 300 μL of HER2Ab-QDs (10 nM) containing DMEM culture 
medium (phenol red and FBS free). All treated plates were incubated for 30 min at 37 °C and the cells 
were washed two times with PBS buffer. Three hundred μL phenol red free DMEM media were filled 
in all plates and cells were examined under confocal laser fluorescence microscopy. For other types of 
QDs for cell staining, similar procedures with the case of HER2Ab-QDs were performed. 
 
3.9. Confocal Fluorescence Microscopy 
 
Confocal fluorescence images were taken with an Olympus confocal inverted microscope 
(FluoView1000) using an oil immersion objective lens (60 ×, N. A. = 1.35). Excitation was performed Sensors 2009, 9                 
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at 405 nm with a LD pumped solid laser. Emission filters of 490-540 nm, 575-620 nm, and 655-755 nm 
were used for the cells incubated with green-, orange-, and red-emitting HER2Ab-QDs. 
4. Conclusions  
We have synthesized three types of HER2Ab-QDs based on EDC/sulfo-NHS, iminothiolane/sulfo-
SMCC, and sulfo-SMCC coupling reactions for fluorescence imaging of HER2 overexpressing cancer 
cells. To conjugate antibody to QDs, we used GSH coated QDs with high quantum yields (0.23−0.39). 
Hydrodynamic size of the HER2 conjugated QDs depended on the coupling reaction for antibody 
conjugation, and the values of the size were ranging from 9.4 nm to 12 nm in diameter. AFM images 
of the HER2Ab-QDs indicate that the number of antibody molecules conjugating to the QD surface is 
limited by the steric hindrance between antibody molecules.  
Fluorescence images of HER2 expression in KPL-4 breast caner cells showed that the colloidal 
stability of HER2Ab-QDs prepared by SMCC coupling are higher than that of HER2Ab-QDs prepared 
by remaining two coupling methods. In addition, the size of HER2Ab-QDs significantly affects on the 
fluorescence imaging of HER2 expression in the KPL-4 cells. Smaller (green-emitting) HER2Ab-QDs 
were rapidly taken up into the inside of the cells by endocytosis or macropinocytosis, while larger 
(red-emitting) HER2Ab-QDs were distributed to the cell surface and slowly taken up. The red-emitting 
(650 nm) HER2Ab-QDs (prepared by using SMCC coupling to reduced antibodies) are most effective 
and quantitative for imaging of HER2 expression in the breast cancer cells.  
The fluorescence imaging of HER2 expression can be performed by using a very low concentration 
(10 nM) of HER2Ab-QDs. Compared with conventional IHC and FISH, the QD-based HER2 
detection method is easy, fast and economic. Since QDs are resistant to photobleaching, quantitative 
evaluation of HER2 expression may be possible by using HER2Ab-QDs. The use of HER2Ab-QDs as 
a fluorescent probe has great potential for the precise determination of HER2 status of breast cancer 
patients in cellular levels. 
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